There is an attractive market for therapies that stop hair loss and prevent disease progression. Globally, several major pharmaceutical companies are actively working to develop new therapeutic products for the treatment of Androgenetic Alopecia. Some of the key players in the market include Cosmo Pharmaceuticals, Kintor Pharmaceutical, Merz Aesthetics, and several others.
DelveInsight’s “Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Androgenetic Alopecia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Androgenetic Alopecia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Androgenetic Alopecia: An Overview
Androgenetic alopecia is a genetically predetermined disorder due to an excessive response to androgens. This condition affects up to 50% of males and females and is characterized by progressive loss of terminal hair of the scalp any time after puberty. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women, the frontal hairline is typically spared with diffuse hair loss at the crown and top of the head, with loss often marked by a wider center part.
Androgenetic Alopecia Market Key Facts
-
As per DelveInsight, the Androgenetic Alopecia Market size was approximately USD 5,600 million in 2021 in the 7MM, which is anticipated to grow by 2032.
-
The total prevalent cases of androgenetic alopecia were more than 194,000,000 in the 7MM in 2021.
-
In the US, females accounted for nearly 30,500,000 cases of androgenetic alopecia out of the total prevalent population in 2021, which is estimated to rise during the forecast period.
-
In EU4 and the UK, males accounted for nearly 52,500,000 prevalent androgenetic alopecia out of the total prevalent cases (about 84,000,000) in 2021, which is expected to increase during the forecast period.
-
Assessments showed that Japan accounted for more than 28,700,000 cases in 2021.
-
The treatment of androgenetic alopecia should be initiated as early as possible, as untreated androgen-dependent alopecia progressively deteriorates. There are several treatment options available for the treatment of hair loss, although currently, only topical minoxidil and oral finasteride have the approval of the Food and Drug Administration (FDA) for the treatment of AGA.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Androgenetic Alopecia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Androgenetic Alopecia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Androgenetic Alopecia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Androgenetic Alopecia Epidemiology Segmented by –
-
Total prevalent cases of Androgenetic Alopecia in the 7MM (2019–2032)
-
Total prevalent cases of Androgenetic Alopecia in males in the 7MM (2019–2032)
-
Total prevalent cases of Androgenetic Alopecia in females in the 7MM (2019–2032)
-
Total diagnosed prevalent cases of Androgenetic Alopecia in males in the 7MM (2019–2032)
-
Total diagnosed prevalent cases of Androgenetic Alopecia in females in the 7MM (2019–2032)
Androgenetic Alopecia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Androgenetic Alopecia market or expected to be launched during the study period. The analysis covers the Androgenetic Alopecia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Androgenetic Alopecia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Androgenetic Alopecia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
Androgenetic Alopecia Therapeutics Analysis
The current treatment plan for androgenetic alopecia mainly includes oral finasteride, topical external use of minoxidil, low-intensity laser, and hair transplantation. Finasteride is a 5a-reductase inhibitor that significantly affects the treatment of androgenetic alopecia; however, it can also exhibit unacceptable side effects in a small subset of patients. Occasionally, side effects persist even after treatment cessation, in the form of the post-finasteride syndrome. Additionally, minoxidil can cause undesirable adverse effects. Currently, low-intensity laser therapy has shown promising results in the treatment of androgenetic alopecia; however, the effectiveness of its treatment remains controversial.
Several major pharma and biotech giants are developing therapies for Androgenetic Alopecia to further improve the treatment scenario. Currently, Kintor Pharma has its Androgenetic Alopecia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Androgenetic Alopecia Therapeutics Market Include:
-
Aclaris Therapeutics
-
Addpharma
-
AndroScience Corporation
-
AnnJi Pharmaceutical
-
Applied Biology, Inc.
-
Biosplice Therapeutics
-
Carmell Therapeutics
-
Cassiopea
-
Cutia Therapeutics
-
Dong-A ST Co., Ltd.
-
Follica
-
Kerastem
-
Kintor Pharmaceutical
And Many Others
Androgenetic Alopecia Drugs Covered in the Report Include:
-
Autologous platelet-rich plasma: Santiste Medical Inc
-
BREEZULA: Cosmo Pharmaceuticals
-
Clascoterone: Cassiopea
-
DLQ01: Dermaliq Therapeutics
-
FOL100: Follicle Pharma
-
KX-826: Kintor Pharma
-
OLX104C: OliX Pharmaceuticals
-
TDM-105795: Technoderma Medicines
-
XEOMIN: Merz Aesthetics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Androgenetic Alopecia Competitive Intelligence Analysis
4. Androgenetic Alopecia Market Overview at a Glance
5. Androgenetic Alopecia Disease Background and Overview
6. Androgenetic Alopecia Patient Journey
7. Androgenetic Alopecia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Androgenetic Alopecia Treatment Algorithm, Current Treatment, and Medical Practices
9. Androgenetic Alopecia Unmet Needs
10. Key Endpoints of Androgenetic Alopecia Treatment
11. Androgenetic Alopecia Marketed Products
12. Androgenetic Alopecia Emerging Drugs and Latest Therapeutic Advances
13. Androgenetic Alopecia Seven Major Market Analysis
14. Attribute Analysis
15. Androgenetic Alopecia Market Outlook (In US, EU5, and Japan)
16. Androgenetic Alopecia Access and Reimbursement Overview
17. KOL Views on the Androgenetic Alopecia Market
18. Androgenetic Alopecia Market Drivers
19. Androgenetic Alopecia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
Related Reports by DelveInsight
Androgenetic Alopecia Pipeline Insight
“Androgenetic Alopecia Pipeline Insight, 2023” report provides comprehensive insights about 12+ companies and 12+ drugs in the Androgenetic Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/